While treatments such as luspatercept have demonstrated sustained efficacy and a manageable safety profile over 5 years in patients with beta-thalassemia (63), the long-term immunological consequences of chronic hepcidin modulation, including its impact on infection susceptibility, are not yet fully elucidated (25). This evidence concerns the gene HAMP and infection.